Product Datasheet
|
Catalog Number |
ADT1014 |
|
Product Name |
Adecatumumab Research Biosimilar |
|
Product Description |
Adecatumumab (MT201) is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. |
|
CAS Number |
503605-66-1 |
|
Clonity |
Monoclonal |
|
Target |
EPCAM[Homo sapiens] |
|
Alias |
MT201, Adecatumumab Research Biosimilar |
|
Host |
CHO Cells |
|
Isotype |
IgG1 |
|
Size |
100ug,1mg,5mg |
|
Mechanism of Action |
Adecatumumab (MT201) is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has been shown to promote the proliferation, migration and invasiveness of breast cancer cells. Moreover, expression of EpCAM is associated with decreased survival in a number of cancer indications, including breast, gall bladder, bile duct, ovarian and ampullary pancreatic cancer. EpCAM has recently been shown to be expressed on cancer stem cells from breast, prostate, colon and pancreatic cancer. Clinical studies have shown a favorable safety profile and that clinical activity depends on the EpCAM target expression. |
|
Buffer |
Supplied in PBS, PH7.5 |
|
Concentration |
Batch dependent, please contact our customer service to get the COAs of current batch |
|
Purity |
>95% as determined by SDS-PAGE |
|
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
|
Shipping Condition |
This product is shipped in blue ice. |
.jpg){kind=logo}
